Sanofi SA $ 100.34 -3.21 (-3.1%)
SNYNF News and Headlines - Sanofi
Sanofi SA (SNY) has made it clear it wants to get into the rapidly growing gene therapy market, and an acquisition may be the fastest route. Rumor has it that the French pharmaceutical giant has its eyes on San Rafael, California-based Biomarin Pharmaceutical Inc. (BMRN).
Speculation heated up after Sanofi announced it was selling about $11 billion worth of shares it owns in Regeneron Pharmaceuticals Inc. (REGN). That would be a nice down payment, but Sanofi will have to dig deeper into its pockets because Biomarin has a market value of nearly $22 billion. Year to date, its shares are
In a June 11 article for GuruFocus, I looked at the R&D efforts underway at the top five spenders in the pharmaceutical industry last year. Now, let’s take a look at the work being done by those in positions five through 10.
R&D budget: €6.02 billion ($6.52 billion)
Change from 2018: +2.2%
Total 2019 revenue: €36.13 billion ($39.15 billion)
R&D budget as percentage of revenue: 16.7%
Sanofi (SNY), under the leadership of former Roche executive John Reed, is reorienting its R&D efforts to strengthen its position in oncology and other specialty care areas, according to FierceBiotech.
There are two distinct approaches that are being adopted by research-focused biopharma companies to counter the Covid-19 pandemic. Some companies are focused on developing vaccines for preventive purposes, whereas others are more focused on drug development to cure the patients who are suffering from the virus.
While giants like Gilead Sciences (GILD) and Sanofi (SNY) are making progress in the development of a drug and vaccine, respectively, a number of small research-focused players have emerged whose candidates are demonstrating promising results in the early phases of testing, causing their stock prices to increase dramatically.
Sorrento Therapeutics (SRNE) is
A company that can speed up drug discovery; one that is already partnering with the world’s 20 biggest drug companies and appears to be just scratching the surface of its potential. Sounds like a winner.
Shareholders would agree wholeheartedly. Since going public in early February with an offering price of $17, Schrodinger Inc.'s (SDGR) stock has more than tripled to $57.
Is it too late for investors to hop aboard? It might be. Four analysts have set a median 12-month price target of $56, according to CNN Money. However, the high target is $67 with the low at $50.
Sanofi’s (SNY) decision to hedge its bet on developing a vaccine for Covid-19 has helped nearly double the year-to-date share price of a Boston-area therapeutics company.
Translate Bio Inc.’s (TBIO) partnership with Sanofi builds on the three-year pact the companies signed in June 2018 to use Translate’s technology called mRNA to develop vaccines for up to five infectious diseases. Given the worldwide pandemic, the Covid-19 vaccine is now front and center.
GENE News reported that Translate Bio CEO Ronald C. Renaud Jr. said the companies hope to begin animal testing in weeks. “We have a goal to be in the
Shares of Lexington, Massachusetts-based biotechnology company Translate Bio Inc. (TBIO) climbed about 7% to nearly $11.50 on March 30 after the company announced its collaboration with Sanofi (SNY) to jointly develop a novel messenger RNA (mRNA) vaccine for Covid-19. The stock has since increased to just under $10.
Perhaps many of the gyrations in the share price of Translate and other smaller-cap pharma stocks indicates investors are overreacting to Covid-19 announcements. A day or two later, they may realize just how difficult it’s going to be to develop an effective vaccine or treatment and the time required. Sure, the U.S.
Dividend investors may want to have a look at the following companies, since they currently have higher dividend yields than the S&P 500. As of April 17, the S&P 500 has a dividend yield of 2.07%. These stocks also represent long-term dividend payers.
The first company under consideration is Unilever NV (UN).
The Dutch household and personal products company’s stock traded at a price of $50.50 per share at close on April 17 for a market capitalization of $119.01 billion.
Based on Friday's closing price, Unilever NV gives a trailing 12-month dividend yield of 3.62% and a forward
In light of countries around the world investing in vaccines to curb future waves of the coronavirus, five pharmaceutical companies with high financial strength and profitability are Alexion Pharmaceuticals Inc. (ALXN), Biogen Inc. (BIIB), Johnson & Johnson (JNJ), Novo Nordisk A/S (NVO) and Bio-Techne Corp. (TECH).
According to John Hopkins University statistics, global cases have eclipsed 2 million as of Thursday, with nearly 640,000 cases in the U.S. The World Health Organization added that the coming weeks are “critical” as cases in Europe reach nearly 1 million.
Companies around the globe share vaccine plans
U.K.-based GlaxoSmithKline PLC
Biotech stocks are once again making headlines as the fight against COVID-19, commonly dubbed the "Wuhan Coronavirus," is well underway. Investors are suddenly searching for attractive opportunities in this sector in the hopes that a successful solution to curb the spreading of the virus will lead to eye-popping capital gains.
While there’s no reason to deny such a possibility, picking the right companies to bet on can be both tricky and complicated. To avoid the many pitfalls of thematic investing based on a temporary development such as a pandemic, a thorough understanding of all the important factors involved is important.
The share price of a clinical-stage oncology company that went public just last week has climbed more than 70% on hopes that it can develop drugs to transform the way cancer is treated.
Redwood City, California-based Revolution Medicines Inc. (RVMD) sold 14 million shares at $17 each on Feb. 13, 2020, raising a total of $238 million (more than twice its original goal). At close on Feb. 18, shares were trading at just over $29.
The six-year-old company will use the funds to push along drug candidates that block certain proteins that cause cancer to grow and thrive. The pharmaceutical
It’s that time of the year when investment professionals provide their prognostications for 2020. Some are forecasting a continuation of the long-running bull market, while others think a 15% to 20% correction may be on the horizon. Of course, as the saying goes, “Opinions are like…well, you know—everyone has one.”
A New York Times article said investors should ignore all these predictions. It is true that the prophets are usually right more than they’re wrong. But that’s only because most of the so-called experts say the market will rise the next year, and seven out of 10 times it
Dr. Jennifer Schneider, the president of Livongo Health Inc. (LVGO), couldn’t have been more succinct in describing what the Mountain View, California-based company does: “make it easier for members to stay healthy." In doing so, the company also hopes to put its investors in the pink.
Livongo is an information technology company that uses its software platform to improve the health of patients with chronic conditions, including hypertension, diabetes and weight issues.
The company had a strong opening when it went public on July 25. Its stock climbed 60% above the initial public offering,
Managed by Jason Kritzer and Samantha Pandolfi, the Boston-based fund invests heavily in the health care space. The portfolio managers look around the world for securities that are not only reasonably priced, but which they believe will grow in value over time.
Based on these criteria, the fund opened positions in Amgen Inc. (AMGN) and CVS Health Corp. (CVS) during the quarter.
Having previously exited a position in Amgen in the third quarter of 2016,
Among large pharmaceutical companies, AbbVie (ABBV) and Bristol-Myers Squibb (BMY) are "getting the most out of their workers." At the other end of the spectrum are Sanofi SA (SNY) and AstraZeneca (AZN), according to a June article in Evaluate.
AbbVie is the clear leader of the pack, as measured by sales per full-time employee. Last year, the company became the first member of Big Pharma to surpass more than $1 million in the category. The company has substantially outpaced its peers every year since it went out on its own in 2011.
Sanofi SA's (SNY) newly minted CEO is looking under the hood to figure out what’s needed to get the company in gear. Shareholders are hoping he’s successful. The French pharmaceutical giant has been stuck in neutral for a while, with its shares off a few dollars from where they were two years ago. In defense of Sanofi’s performance, the stock has outperformed the SPDR S&P Pharmaceuticals Exchange-Traded Fund (XPH)
Paul Hudson, 51, who came to Sanofi from Novartis early last month, has been on what he calls a “listening tour,” site to site, country to country, according to an Oct.
In a Sept. 23 article, GuruFocus highlighted three of the 15 private and independent biotechs recognized by a key industry publication for their innovation. As suggested in the piece, investors may want to keep an eye on these firms, many of which could eventually go public. They could also come under the wing of an established member of pharma, bringing the acquirer a novel platform or helping it move into growing areas of therapy. Both could substantially boost the valuation of the parent.
For the first time in 2019, FierceBiotech considered foreign firms for recognition. One that made
If it’s true that busy hands are happy hands, then the management team at Pfizer Inc. (PFE) must be ecstatic.
In just the past few months, the company has:
- Agreed to spin off Upjohn, the manufacturer of Pfizer’s drugs that no longer enjoy patent protection, and combine the unit with Mylan (MYL), a U.K-based generic company.
- Acquired Array to boost its biotech pipeline in a deal valued at about $11.4 billion.
- Announced it is investing $500 million in a gene therapy manufacturing plant in North Carolina to complement money it has already socked into other facilities aimed at producing
Given the recent softening in the shares of uniQure (QURE), now may be the time to buy into the rumored takeover target.
The stock price of the Amsterdam-based biotechnology firm was up to more than $82 in mid-June, when buyout speculation was hot and heavy. Since then, the shares have fallen to $67. That’s still well above their 52-week low of $22, so many longer-terms investors have already pocketed a bundle. If anything, the drop in its market cap to $2.5 billion certainly makes the company more affordable for an acquirer.
It may be attractive to investors for
Chronic disease management company Livongo Health is helping break the drought of digital health companies going public. The Silicon Valley-based company expects to raise $100 million in its initial public offering and will be listed on the Nasdaq later this year under the symbol “LVGO.” The company could be valued at $2 billion.
Digital health funding has been in the doldrums prior to the latest wave of companies planning to go public. A Rock Health Report revealed that in the first quarter of 2019, digital health investments were just under $1 billion, about half of the amount invested in
According to the GuruFocus All-in-One Screener, the following companies look cheap since they are trading with low price-sales ratios.
Shares of Amgen Inc. (AMGN) are trading around $184 with a price-sales ratio of 5.02 and a price-earnings ratio of 14.73.
The biotechnology company has a market cap of $112.53 billion. The stock has risen at an annualized rate of 14.77% over the last 10 years.
The discounted cash flow calculator gives the stock a fair value of $158, suggesting it is overpriced by 16%. The Peter Lynch earnings line gives the stock a fair value of $177.
|2020-06-24 $ 105.25 (-2.22%)|
|2020-06-23 $ 107.64 (1.24%)|
|2020-04-27 $ 103 (3.04%)|
|2020-04-24 $ 99.96 (5.39%)|